Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.

Blower SM, Koelle K, Kirschner DE, Mills J.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3618-23.

2.

Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.

Das AT, Zhou X, Vink M, Klaver B, Berkhout B.

Expert Rev Vaccines. 2002 Oct;1(3):293-301. Review.

PMID:
12901570
3.

AIDS vaccine: efficacy, safety and ethics.

Veljkovic V, Veljkovic N, Glisic S, Ho MW.

Vaccine. 2008 Jun 6;26(24):3072-7. doi: 10.1016/j.vaccine.2007.11.061. Epub 2007 Dec 17.

PMID:
18164521
5.

Using SHIVs to develop an anti-HIV-1 live-attenuated vaccine.

Kuwata T, Miura T, Hayami M.

Trends Microbiol. 2001 Oct;9(10):475-80.

PMID:
11597447
6.

Progress in the development of an HIV-1 vaccine.

Letvin NL.

Science. 1998 Jun 19;280(5371):1875-80. Review.

PMID:
9632379
7.

Preventive HIV-1 vaccines: where are we going?

Kent SJ.

Int J STD AIDS. 1998 Dec;9(12):715-9. Review.

PMID:
9874116
8.

India targets local HIV strain in test of AIDS vaccine.

Jayaraman KS.

Nature. 2004 Jan 15;427(6971):185. No abstract available.

PMID:
14724601
9.

Particle-based vaccines for HIV-1 infection.

Young KR, Ross TM.

Curr Drug Targets Infect Disord. 2003 Jun;3(2):151-69. Review.

PMID:
12769792
10.

Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.

Celentano DD, Beyrer C, Natpratan C, Eiumtrakul S, Sussman L, Renzullo PO, Khamboonruang C, Nelson KE.

AIDS. 1995 Sep;9(9):1079-83.

PMID:
8527082
11.

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.

Girard MP, Osmanov S, Assossou OM, Kieny MP.

Vaccine. 2011 Aug 26;29(37):6191-218. doi: 10.1016/j.vaccine.2011.06.085. Epub 2011 Jun 28. Review.

PMID:
21718747
12.

A live-virus "suicide" vaccine for human immunodeficiency virus.

Kestler HW, Chakrabarti BK.

Cleve Clin J Med. 1997 May;64(5):269-74. Review.

PMID:
9149478
13.

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Mooij P, Bogers WM, Oostermeijer H, Koornstra W, Ten Haaft PJ, Verstrepen BE, Van Der Auwera G, Heeney JL.

J Virol. 2000 May;74(9):4017-27.

14.

Development of prophylactic AIDS vaccines: the current state of affairs.

Hanke T.

Curr Opin Mol Ther. 2003 Feb;5(1):25-32. Review.

PMID:
12669467
15.

Live attenuated AIDS viruses as vaccines: promise or peril?

Ruprecht RM.

Immunol Rev. 1999 Aug;170:135-49. Review.

PMID:
10566148
16.

Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

Fonseca MG, Forsythe S, Menezes A, Vuthoori S, Possas C, Veloso VG, Lucena Fde F, Stover J.

PLoS One. 2010 Jul 23;5(7):e11736. doi: 10.1371/journal.pone.0011736. Erratum in: PLoS One. 2010 Aug 18;5(8) doi: 10.1371/annotation/4fd10061-5a1e-4164-833e-34943a74301c.. Veloso, Valdiléa [corrected to Veloso, Valdiléa Gonçalves].

17.

[An update and the outlook in vaccination against HIV/AIDS].

Ivan A, Azoicăi D, Mitroi I.

Rev Med Chir Soc Med Nat Iasi. 1991 Jan-Jun;95(1-2):207-10. Romanian. No abstract available.

PMID:
1823419
18.

An attenuated vaccine for AIDS?

Beale J.

Lancet. 1995 May 27;345(8961):1318-9.

PMID:
7752750
19.

Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine.

Igarashi T, Ami Y, Yamamoto H, Shibata R, Kuwata T, Mukai R, Shinohara K, Komatsu T, Adachi A, Hayami M.

J Gen Virol. 1997 May;78 ( Pt 5):985-9.

PMID:
9152414
20.

A new approach to AIDS research and prevention: the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines.

Haga T, Kuwata T, Ui M, Igarashi T, Miyazaki Y, Hayami M.

Microbiol Immunol. 1998;42(4):245-51. Review.

Supplemental Content

Support Center